Micro RNAs to Predict Response to Androgen Deprivation Therapy

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Medical College of Wisconsin
Study ID
NCT02366494
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
21 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Bicalutamide — DRUG
    ANDROGEN BLOCKADE
  • Leuprolide — DRUG
    ANDROGEN BLOCKADE
  • Goserelin — DRUG
    ANDROGEN BLOCKADE
  • Triptorelin — DRUG
    ANDROGEN BLOCKADE
  • Docetaxel — DRUG
    Chemo hormonal therapy
  • Abiraterone — DRUG
    Chemo hormonal therapy
  • Apalutamide — DRUG
    Nonsteroidal antiandrogen medication
  • Enzalutamide — DRUG
    Nonsteroidal antiandrogen medication

Study Details

Identify exosomal micro RNA that predict responses to ADT

Key Dates

Start date
Apr 29, 2015
Status verified
Nov 2024
Primary completion
May 11, 2021
Completion
May 11, 2021

Study Design

Enrollment
42 participants (actual)

Arms

  • Arm: Androgen blockade
    Androgen DeprivationTherapy or Complete Androgen Blockade
  • Arm: Hormonal Therapy and Chemotherapy
    Hormonal therapy, novel oral hormonal therapy (abiraterone/apalutamide/enzalutamide) and chemotherapy (docetaxel)

Primary Outcome Measure

Identify five most prevalent exosomal microRNAs that predict response to androgen deprivation therapy based treatment. [ Time Frame: Up to two years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Froedtert HospitalMilwaukeeWisconsin53226-

Find similar trials in Milwaukee, WI

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Froedtert Hospital· Milwaukee, WI

Related Studies